^
    Back
    Association details:
    Biomarker:KRAS G12
    Cancer:Ovarian Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Excerpt:
    ERBITUX is not indicated for the treatment of patients with CRC that harbor somatic mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either K-Ras or N-Ras and hereafter is referred to as “Ras” or when the Ras status is unknown.
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Oncol Rep
    Title:

    Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations

    Excerpt:
    In the present study, cetuximab was unable to inhibit growth of a cell line that had a mutation in exon 2 of the KRAS gene.
    DOI:
    https://doi.org/10.3892/or.2012.1626